Charles Schwab Investment Management Inc. Buys 14,300 Shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS)

Charles Schwab Investment Management Inc. raised its position in shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) by 91.3% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 29,968 shares of the company’s stock after buying an additional 14,300 shares during the quarter. Charles Schwab Investment Management Inc.’s holdings in Corvus Pharmaceuticals were worth $160,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of the company. State Street Corp raised its stake in shares of Corvus Pharmaceuticals by 48.2% during the 3rd quarter. State Street Corp now owns 178,246 shares of the company’s stock worth $941,000 after acquiring an additional 57,943 shares in the last quarter. Jane Street Group LLC purchased a new position in Corvus Pharmaceuticals in the third quarter worth $265,000. XTX Topco Ltd acquired a new position in shares of Corvus Pharmaceuticals during the third quarter worth $74,000. Geode Capital Management LLC lifted its holdings in shares of Corvus Pharmaceuticals by 22.4% during the 3rd quarter. Geode Capital Management LLC now owns 563,009 shares of the company’s stock valued at $2,974,000 after purchasing an additional 102,869 shares during the last quarter. Finally, Virtu Financial LLC acquired a new stake in shares of Corvus Pharmaceuticals in the 3rd quarter worth $83,000. 46.64% of the stock is currently owned by institutional investors.

Corvus Pharmaceuticals Price Performance

Shares of CRVS opened at $3.17 on Wednesday. The company’s fifty day moving average price is $4.53 and its 200-day moving average price is $6.05. Corvus Pharmaceuticals, Inc. has a 1-year low of $1.30 and a 1-year high of $10.00. The firm has a market capitalization of $215.99 million, a PE ratio of -3.41 and a beta of 0.91.

Corvus Pharmaceuticals (NASDAQ:CRVS) last posted its quarterly earnings results on Tuesday, March 25th. The company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.06). As a group, research analysts anticipate that Corvus Pharmaceuticals, Inc. will post -0.63 EPS for the current fiscal year.

Analysts Set New Price Targets

Several brokerages recently issued reports on CRVS. HC Wainwright reaffirmed a “buy” rating and set a $11.00 target price on shares of Corvus Pharmaceuticals in a research report on Wednesday, March 26th. Oppenheimer restated an “outperform” rating and set a $15.00 price target (up previously from $14.00) on shares of Corvus Pharmaceuticals in a research note on Wednesday, March 26th. One equities research analyst has rated the stock with a sell rating, three have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $15.67.

About Corvus Pharmaceuticals

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.